Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing while tracking clinical milestones for Vivitrol, Aristada and Lybalvi can consume your entire day. Alkermes’ disclosures blend scientific detail with complex revenue recognition rules, leaving many investors searching line by line for what matters most.
Stock Titan solves this problem by coupling real-time EDGAR feeds with AI-powered summaries that turn technical language into plain English. Whether you need the Alkermes quarterly earnings report 10-Q filing or an Alkermes annual report 10-K simplified, our system highlights trial updates, segment revenue, and key risk factors in seconds. You’ll also receive instant alerts on every Alkermes insider trading Form 4 transactions entry—so you can monitor Alkermes executive stock transactions Form 4 before market reactions.
Looking for something specific? Our platform answers the exact questions professionals ask:
- “How did R&D spend shift this quarter?” — see it in the Alkermes earnings report filing analysis
- “Any new 8-K disclosures?” — check Alkermes 8-K material events explained with one click
- “What’s in the latest proxy?” — explore Alkermes proxy statement executive compensation without scrolling hundreds of pages
Every filing—10-K, 10-Q, 8-K, S-8, and even niche forms—arrives the moment it hits EDGAR, complete with Alkermes Form 4 insider transactions real-time notifications. Use our AI to compare quarter-over-quarter product sales, understand safety-signal language, and evaluate pipeline timelines, all while understanding Alkermes SEC documents with AI. Complex biotech disclosures, finally clear.
Form 4 alerts investors that Richardson Electronics’ EVP-Global Supply Chain, Kathleen McNally, surrendered a total of 902 common shares on 17–18 Jul 2025 to cover withholding taxes on previously vested restricted-stock awards. The transactions are coded “F,” indicating no open-market sale; shares were withheld by the company at the NASDAQ closing prices of $9.78 and $9.58, respectively.
Following the withholdings, McNally’s direct beneficial ownership declined from 42,071 to 41,169 shares—a reduction of roughly 2.1 % of her position and immaterial relative to Richardson’s 12.0 million shares outstanding. No derivative securities were involved, and there is no indication of a change in McNally’s investment intent. The filing is therefore administrative rather than a signal of insider sentiment.
FAQ
What is the current stock price of Alkermes Plc (ALKS)?
What is the market cap of Alkermes Plc (ALKS)?
What is the core focus of Alkermes plc?
How does Alkermes generate its revenue?
What therapeutic areas does Alkermes specialize in?
Where are Alkermes' key operational facilities located?
How does Alkermes maintain its competitive edge?
What is unique about Alkermes' research and development strategy?
Can you describe the company’s approach to clinical trials?
How does Alkermes demonstrate expertise and trustworthiness?
